Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Discover yearly leaders among index funds and understand how performance shifts across periods, helping you choose resilient options.
27,236 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Barclays slashed Coinbase’s price target to $107 following aQ1 2026 revenue miss, highlighting a tug-of-war between c...
Is AppLovin undervalued stock buy? This article breaks down the business, growth outlook, and valuation framework to ...
Lenders are adopting ai-powered data remaps builders’ to accelerate land acquisitions and adjust financing terms amid...
A leaked Meta audio from an April 30 all-hands meeting signals a shift toward leveraging compute and internal output ...
Gas prices are nudging shoppers toward membership clubs, with Costco delivering a strong quarterly performance. The t...
Dell Technologies shares have surged about 120% in a blistering run, pushing the stock toward record levels as AI inf...
The Federal Housing Administration announces the resignation of Commissioner Frank Cassidy, effective June 1, ending ...
A new wave of consolidation is reshaping fintech markets as AI integration and healthier balance sheets spur potentia...
Air-taxi stocks climb on a broad risk-on rally, with EHANG up about 18%, ARCHER up roughly 10%, and JOBY gaining abou...
Insilico Medicine and SK Biopharmaceuticals unveiled a milestone collaboration worth up to $2.5 billion to develop ne...
Bitcoin’s bear market struggle is driving layoffs and automation in crypto firms even as banks and fintechs chase big...